作者
A Das, FC Henderson, M Alshareef, GBF Porto, I Kanginakudru, LK Infinger, WA Vandergrift, SM Lindhorst, AK Varma, SJ Patel, D Cachia
发表日期
2021/3
期刊
Clinical and Translational Oncology
卷号
23
页码范围
612-619
出版商
Springer International Publishing
简介
Background
Glioblastoma (GB) remains an incurable and deadly brain malignancy that often proves resistant to upfront treatment with temozolomide. Nevertheless, temozolomide remains the most commonly prescribed FDA-approved chemotherapy for GB. The DNA repair protein methylguanine-DNA methyl transferase (MGMT) confers resistance to temozolomide. Unsurprisingly temozolomide-resistant tumors tend to possess elevated MGMT protein levels or lack inhibitory MGMT promotor methylation. In this study, cultured human temozolomide resistance GB (43RG) cells were introduced to the MGMT inhibitor O6-benzylguanine combined with temozolomide and either LY2835219 (CDK 4/6 inhibitor) or LY2157299 (TGF-βRI inhibitor) seeking to overcome GB treatment resistance.
Methods
Treatment effects were assessed using MTT (3-(4,5 …
学术搜索中的文章
A Das, FC Henderson, M Alshareef, GBF Porto… - Clinical and Translational Oncology, 2021